Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens

GAR-936 is a new semisynthetic glycylcycline with a broad antibacterial spe ctrum, including tetracycline-resistant strains. The in vitro activities of GAR-936, minocycline, doxycycline, tetracycline, moxifloxacin, penicillin G, and erythromycin were determined by agar dilution methods against 268 ae robic and 148 anaerobic strains of bacteria (including Pasteurella, Eikenel la, Moraxella, Bergeyella, Neisseria, EF-4, Bacteroides, Prevotella, Porphy romonas, Fusobacterium, Staphylococcus, Streptococcus, Enterococcus, Coryne bacterium, Propionibacterium, Peptostreptococcus, and Actinomyces) isolated from infected human and animal bite wounds in humans, including strains re sistant to commonly used antimicrobials. GAR-936 was very active, with an M IC at which 90% of the strains are inhibited (MIC90) of less than or equal to 0.25 mu g/ml, against all aerobic gram-positive and -negative strains, i ncluding tetracycline-resistant strains of Enterococcus, Streptococcus, and coagulase-negative staphylococci, except for Eikenella corrodens (MIC90, l ess than or equal to 4 mu g/ml). GAR-936 was also very active against all a naerobic species, including tetracycline-, doxycycline-, and minocycline-re sistant strains of Prevotella spp., Porphyromonas spp., Bacteroides tectum, and Peptostreptococcus spp. with an MIC90 of less than or equal to 0.25 mu g/ml. Erythromycin- and moxifloxacin-resistant fusobacteria were susceptib le to GAR-936, with an MIC90 of 0.06 mu g/ml.